
    
      This is a multiple-dose, randomized, placebo-controlled crossover study of the efficacy and
      safety of XP19986 SR1 in subjects with spasticity due to spinal cord injury. Three cohorts of
      subjects are randomized to receive XP19986 SR1 10 mg every 12 hrs or 20 mg every 12 hrs or 30
      mg every 12 hrs in one treatment segment and placebo every 12 hrs in the alternate treatment
      segment. Each subject serves as their own control in this cross-over study.
    
  